[fullofbeans]

Also
curcumin, a well-known inhibitor of NF-kB activity

http://www.transonc.com/abstract.php?msid=101

Curcumin promotes apoptosis, increases chemosensitivity and inhibits nuclear factor-kappa beta in esophageal adenocarcinoma.

Wibisono Hartojo, Amy L Silvers, Dafydd G Thomas, Christopher W Seder, Lin Lin, Hyma R Rao, Zhuwen Wang, Joel K Greenson, Thomas J Giordano, Mark B Orringer, Alnawaz Rehemtulla, Mahaveer S Bhojani, David G Beer and Andrew C. Chang

Year 2010, Volume 3, Issue 2
Abstract
The transcription factor, Nuclear Factor-kB (NF-kB), plays a central role as a key mediator of cell survival and proliferation, and its activation may confer increased tumor chemoresistance. Curcumin, an orally-available naturally-occurring compound, has been shown to inhibit NF-kB and has a potential role in cancer chemoprevention. We investigated the effects of curcumin on NF-kB activity, on cell viability, and as a chemosensitizing agent with 5-fluorouracil (5FU) or cisplatin (CDDP) in esophageal adenocarcinoma (EAC). Oligonucleotide microarray analysis of 46 cases, consisting of Barrett’s metaplasia, low-grade dysplasia, high-grade dysplasia and EAC, showed increased expression of NF-kB and IkB kinase subunits and decreased effector caspase expression in EAC compared to Barrett’s metaplasia. Stromal expression of both IkB and phospho-IkB was detected in several EAC samples by tissue microarray (TMA) analysis. Curcumin alone inhibited NF-kB activity and induced apoptosis in both Flo-1 and OE33 EAC cell lines as determined by Western blotting, NF-kB reporter assays, and Caspase-Glo 3/7 assays. It also increased 5FU- and CDDP-induced apoptosis in both cell lines. These data suggest that activation of NF-kB and inhibition of apoptosis may play a role in the progression from Barrett’s metaplasia to esophageal adenocarcinoma. In addition, curcumin, a well-known inhibitor of NF-kB activity, was shown to increase apoptosis and enhance both 5FU and CDDP-mediated chemosensitivity, suggesting that it may have potential application in the therapy of patients with esophageal adenocarcinoma.